<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="44364"><DrugName>buspirone</DrugName><DrugNamesKey><Name id="42805124">BuSpar</Name><Name id="42757593">buspirone</Name></DrugNamesKey><DrugSynonyms><Name><Value>buspirone</Value><Types><Type>BANN</Type><Type>INN</Type></Types></Name><Name><Value>BuSpar</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>36505-84-7</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="15065">Bristol-Myers Squibb Co</CompanyOriginator><CompaniesPrimary><Company id="15065">Bristol-Myers Squibb Co</Company></CompaniesPrimary><CompaniesSecondary><Company id="15873">Elan Corp plc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="44364" type="Drug"><TargetEntity id="115228" type="siDrug">Buspirone hydrochloride</TargetEntity><TargetEntity id="129927" type="siDrug">Buspirone</TargetEntity></SourceEntity><SourceEntity id="15065" type="Company"><TargetEntity id="4295903619" type="organizationId">Bristol-Myers Squibb Co</TargetEntity></SourceEntity><SourceEntity id="15873" type="Company"><TargetEntity id="4295874887" type="organizationId">Perrigo Corporation DAC</TargetEntity></SourceEntity><SourceEntity id="25" type="ciIndication"><TargetEntity id="10057666" type="MEDDRA"/><TargetEntity id="D001008" type="MeSH"/><TargetEntity id="-1384065283" type="omicsDisease"/><TargetEntity id="30" type="siCondition"/></SourceEntity><SourceEntity id="34" type="ciIndication"><TargetEntity id="F90" type="ICD10"/><TargetEntity id="10003736" type="MEDDRA"/><TargetEntity id="D001289" type="MeSH"/><TargetEntity id="-197354408" type="omicsDisease"/><TargetEntity id="87" type="siCondition"/></SourceEntity><SourceEntity id="6" type="Action"><TargetEntity id="220" type="Mechanism">5-HT1A Receptor Agonists</TargetEntity></SourceEntity><SourceEntity id="867" type="Action"><TargetEntity id="962" type="Mechanism">Drugs Affecting Brain Dopamine</TargetEntity><TargetEntity id="136" type="Mechanism">Drugs Acting on Dopaminergic Transmission</TargetEntity></SourceEntity><SourceEntity id="PTGT-00011" type="ciTarget"><TargetEntity id="100215858133503" type="siTarget">5-hydroxytryptamine receptor 1A</TargetEntity><TargetEntity id="4469" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Anxiety disorder - UK - Dec-1987</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="25">Anxiety disorder</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="34">Attention deficit hyperactivity disorder</Indication></IndicationsSecondary><ActionsPrimary><Action id="6">5-HT 1a receptor agonist</Action></ActionsPrimary><ActionsSecondary><Action id="2942">Anxiolytic</Action><Action id="867">Dopamine modulator</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology><Technology id="585">Oral formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>N5C</Code><Name>TRANQUILLISERS</Name></Ephmra></EphmraCodes><LastModificationDate>2018-06-15T05:08:55.000Z</LastModificationDate><ChangeDateLast>2018-06-15T00:00:00.000Z</ChangeDateLast><AddedDate>2003-03-26T16:53:15.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Buspirone (Buspar) is an anti-anxiety agent that is not chemically or pharmacologically related to the benzodiazepines, barbiturates, or other sedative/anxiolytic drugs. It was developed and launched in 1986 by &lt;ulink linkID="15065" linkType="Company"&gt;Bristol-Myers Squibb Co&lt;/ulink&gt; (BMS), as tablets for oral administration, for the management of anxiety disorders and the short-term relief of the symptoms of anxiety [&lt;ulink linkID="482472" linkType="Reference"&gt;482472&lt;/ulink&gt;], [&lt;ulink linkID="553873" linkType="Reference"&gt;553873&lt;/ulink&gt;]. In  1986, the product was approved in France and other European countries [&lt;ulink linkID="1347661" linkType="Reference"&gt;1347661&lt;/ulink&gt;]. In June 1987, the product was approved in the UK [&lt;ulink linkID="2024916" linkType="Reference"&gt;2024916&lt;/ulink&gt;]. In December 1988, Buspar was approved  in Spain, however, in December 2011, it was withdrawn in Spain [&lt;ulink linkID="1356764" linkType="Reference"&gt;1356764&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;BMS was also developing a transdermal patch formulation of buspirone in collaboration with &lt;ulink linkID="15873" linkType="Company"&gt;&lt;/ulink&gt;&lt;ulink linkID="15873" linkType="Company"&gt;Elan Corp plc&lt;/ulink&gt;, for the treatment of anxiety, depression and attention deficit hyperactivity disorder. In June 1997, the patch was in phase III trials for these three indications [&lt;ulink linkID="266509" linkType="Reference"&gt;266509&lt;/ulink&gt;], however no further development has been reported since 1998 [&lt;ulink linkID="335669" linkType="Reference"&gt;335669&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;The product patent for buspirone expired in 1990; however, the US anxiolytic method of use patent for buspirone, &lt;ulink linkID="IN898395" linkType="Patent"&gt;US-04182763&lt;/ulink&gt;, did not expire until 2000, including a six month pediatric extension. Patents outside of the US expired in 1999 [&lt;ulink linkID="536721" linkType="Reference"&gt;536721&lt;/ulink&gt;]. The US patent &lt;ulink linkID="IN1487545" linkType="Patent"&gt;US-05015646&lt;/ulink&gt;, which with pediatric extension would expire on November 14, 2008, covers a crystalline polymorphic form of buspirone hydrochloride; however, this patent has not been successful in protecting against generic competition and has now been delisted from the Orange Book. In addition, BMS has waived its rights to two periods of marketing exclusivity in the US. BMS also tried to gain further protection for buspirone using &lt;ulink linkID="IN2729540" linkType="Patent"&gt;US-06150365&lt;/ulink&gt;, but this patent was contested and has also been delisted from the Orange Book. Final marketing approval for generic buspirone took place in March 2001 [&lt;ulink linkID="536721" linkType="Reference"&gt;536721&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Generic buspirone is widely available, with&lt;ulink linkID="18439" linkType="Company"&gt; Mylan Laboratories Inc&lt;/ulink&gt; (&lt;ulink linkID="51012" linkType="Drug"&gt;buspirone, Mylan&lt;/ulink&gt;) receiving exclusivity for the 15 mg dosage form, and &lt;ulink linkID="21717" linkType="Company"&gt;Watson Pharmaceuticals Inc&lt;/ulink&gt; obtaining exclusivity for the 5 mg and 10 mg dosage forms in March 2001 [&lt;ulink linkID="468343" linkType="Reference"&gt;468343&lt;/ulink&gt;], [&lt;ulink linkID="553968" linkType="Reference"&gt;553968&lt;/ulink&gt;], [&lt;ulink linkID="553970" linkType="Reference"&gt;553970&lt;/ulink&gt;]. By August 2004, several other companies were marketing generics. Legal disputes between Bristol-Myers Squibb and Mylan regarding buspirone were fully resolved in February 2003 [&lt;ulink linkID="553985" linkType="Reference"&gt;553985&lt;/ulink&gt;]. By April 2006, a Paragraph IV Certification for buspirone at doses 5, 7.5, 10, 15 and 30 mg was submitted to the FDA [&lt;ulink linkID="663902" linkType="Reference"&gt;663902&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; In April 2003, the drug was launched as branded generic Itagil in Portugal [&lt;ulink linkID="1368781" linkType="Reference"&gt;1368781&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By October 2010, Buspar had been withdrawn from the US market. The FDA stated that the drug was not withdrawn from sale for reasons of safety or effectiveness and that approval of ANDAs that reference the  product would not be affected [&lt;ulink linkID="1491368" linkType="Reference"&gt;1491368&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In September 1986, Buspar was approved in the US by the FDA [&lt;ulink linkID="1484863" linkType="Reference"&gt;1484863&lt;/ulink&gt;] and subsequently launched. However, by October 2010, Buspar tablets 10, 15, and 30 mg had been withdrawn from the US market. The FDA stated that the drug was not withdrawn from sale for reasons of safety or effectiveness [&lt;ulink linkID="1491368" linkType="Reference"&gt;1491368&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In  1986, the product was approved in France and other European countries [&lt;ulink linkID="1347661" linkType="Reference"&gt;1347661&lt;/ulink&gt;]. Buspar tablets were approved in the UK in June 1987 [&lt;ulink linkID="2024916" linkType="Reference"&gt;2024916&lt;/ulink&gt;]. In December 1988, Buspar was approved  in Spain and by December 2011, it  had been withdrawn in Spain [&lt;ulink linkID="1356764" linkType="Reference"&gt;1356764&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="25">Anxiety disorder</Indication><StatusDate>1987-12-31T00:00:00.000Z</StatusDate><Source id="2024916" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="25">Anxiety disorder</Indication></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="FR">France</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="25">Anxiety disorder</Indication><StatusDate>2010-04-28T00:00:00.000Z</StatusDate><Source id="1347661" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="ES">Spain</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="25">Anxiety disorder</Indication><StatusDate>2011-12-28T00:00:00.000Z</StatusDate><Source id="1356764" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="25">Anxiety disorder</Indication><StatusDate>2010-10-10T00:00:00.000Z</StatusDate><Source id="1491368" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15873">Elan Corp plc</Company><Country id="WO">World</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="34">Attention deficit hyperactivity disorder</Indication><StatusDate>1998-12-01T00:00:00.000Z</StatusDate><Source id="335669" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="FR">France</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="25">Anxiety disorder</Indication><StatusDate>1986-08-07T00:00:00.000Z</StatusDate><Source id="1347661" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="ES">Spain</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="25">Anxiety disorder</Indication><StatusDate>1988-12-01T00:00:00.000Z</StatusDate><Source id="1356764" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="25">Anxiety disorder</Indication><StatusDate>1986-09-29T00:00:00.000Z</StatusDate><Source id="1484863" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="25">Anxiety disorder</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="GB">UK</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="25">Anxiety disorder</Indication><StatusDate>1987-06-11T00:00:00.000Z</StatusDate><Source id="2024916" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15873">Elan Corp plc</Company><Country id="WO">World</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="34">Attention deficit hyperactivity disorder</Indication><StatusDate>1997-10-17T00:00:00.000Z</StatusDate><Source id="266509" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00011"><Name>5-HT 1a receptor</Name><SwissprotNumbers><Swissprot>P08908</Swissprot><Swissprot>P19327</Swissprot><Swissprot>Q64264</Swissprot><Swissprot>Q6XXX9</Swissprot><Swissprot>Q6XXY0</Swissprot><Swissprot>Q9N296</Swissprot><Swissprot>Q9N297</Swissprot><Swissprot>Q9N298</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="15065">Bristol-Myers Squibb Co</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20348">Teva Pharmaceutical Industries Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>c1cnc(nc1)N2CCN(CC2)CCCCN3C(=O)CC4(CCCC4)CC3=O</Smiles></StructureSmiles><Deals><Deal id="144851" title="Actavis to commercialize Bristol-Myers' buspirone "/></Deals><PatentFamilies><PatentFamily id="1016683" number="WO-09635425" title="A pharmaceutical composition useful in treating alcohol dependence or abuse comprising at least one partial agonist of 5-TH1A receptors and at least one selective inhibitor of monoamino-oxidase."/><PatentFamily id="1040262" number="EP-00285008" title="&lt;para&gt;The use of buspirone for preparing a pharmaceutical composition for the treatment of alcohol abuse&lt;/para&gt;&lt;para&gt; &lt;/para&gt;"/><PatentFamily id="1049031" number="EP-00220696" title="Use of buspirone for preparing pharmaceutical compositions for alleviation of panic disorders"/><PatentFamily id="107569" number="WO-2006128255" title="Method and composition for transdermal drug delivery"/><PatentFamily id="1126578" number="EP-00442423" title="Use of buspirone in sleep apneas"/><PatentFamily id="1156319" number="CN-100379422" title="A polypropylene composition with buspirone"/><PatentFamily id="1171313" number="WO-02102988" title="Method for neural stem cell differentiation using 5ht-1a agonists"/><PatentFamily id="1207760" number="KR-00159088" title="Pharmaceutical compositions containing buspirone for the treatment of melancholic depression"/><PatentFamily id="123552" number="WO-00134124" title="Use of 5HT-1A-serotonine receptor agonists for treating genetic or functional rhythm disorders in the respiratory system"/><PatentFamily id="1315920" number="US-07109206" title="Methods and compositions for the rapid and enduring relief of inadequate myocardial function"/><PatentFamily id="1353215" number="EP-00655449" title="A process for preparing N-( 2-pyrimidyl) piperazinyl butyl imides"/><PatentFamily id="1353767" number="US-05637314" title="Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis."/><PatentFamily id="1468074" number="US-09789155" title="Methods of improving behavioral therapies"/><PatentFamily id="1472603" number="WO-2004084900" title="Topical formulation and use of buspirone"/><PatentFamily id="1482843" number="US-06350471" title="Tablet comprising a delayed release coating."/><PatentFamily id="1496514" number="EP-00395192" title="Process for the preparation of 8-(4-(4-pyrimidin-2- yl-piperazinyl)-butyl)-8-aza-spiro(4.5)decane-7,9-dione (buspiron)"/><PatentFamily id="1500720" number="WO-09605817" title="Medicament for treatment or prophylaxis of incontinence."/><PatentFamily id="1547933" number="WO-2008060397" title="Method of treating thermoregulatory disfunction"/><PatentFamily id="1578698" number="WO-00024386" title="Method Of Making Pressure Sensitive Adhesive Matrix Patches Containing Hydrophilic Salts Of Drugs"/><PatentFamily id="159249" number="WO-2011064769" title="Methods and pharmaceutical compositions for the treatment of hot flashes"/><PatentFamily id="1637054" number="CN-102391282" title="Method for purifying buspirone from river locust"/><PatentFamily id="1639290" number="EP-00634411" title="Process For The Preparation Of 8-(4'C4&quot;-(Pyrimidin-2'''-Yl)-Piperazin-1''-Yl)-Butyl)-8-Aza-Spiro(4,5)Decan-7,9-Dione And Of Its Hydrochlorides Of High Purity."/><PatentFamily id="1656586" number="US-04182763" title="Buspirone Anti-Anxiety Method"/><PatentFamily id="1683531" number="WO-00012067" title="Novel pharmaceutical salt form"/><PatentFamily id="1687560" number="WO-09422448" title="Topical and systemic application of buspirone or derivatives thereof for treatment of pathological conditions associated with immune responses."/><PatentFamily id="1724179" number="WO-09807410" title="Methods for the production of protein particles useful for delivery of pharmacological agents"/><PatentFamily id="1725096" number="WO-09824411" title="Method for oral administration of buspirone."/><PatentFamily id="1792398" number="EP-00304941" title="Pharmaceutically useful polymorphic modification of buspirone."/><PatentFamily id="1805459" number="WO-00168073" title="Method for improving respiratory function and inhibiting muscular degeneration"/><PatentFamily id="1829227" number="EP-01266656" title="Anionic exchange polymer complexes of buspirone"/><PatentFamily id="1866354" number="EP-00481207" title="Method for preventing or inhibiting loss of cognitive function employing a combination of an ace inhibitor and a drug that acts at serotonin receptors."/><PatentFamily id="1936094" number="WO-08704621" title="Treatment of sexual dysfunction with buspirone"/><PatentFamily id="1940367" number="EP-00419237" title="Treatment of non ulcerative dyspepsia with cyproheptadine and method for the diagnosis of a dysfunction of the central 5-HT1-A receptors."/><PatentFamily id="1974978" number="WO-09402623" title="Blood levels of CCK peptides relative to panic disorder treatment."/><PatentFamily id="2012768" number="DE-04039631" title="Neuro-protective combination"/><PatentFamily id="2017974" number="CH-00682563" title="Substituted amido:butyl-piperazinyl-pyrimidine preparation - from 2-piperazinyl-pyrimidine via new butenyl compound, used in psychiatry e.g. as tranquilliser buspirone"/><PatentFamily id="2018733" number="EP-00662321" title="Method for producing osmosis-controlled tablets avoiding the use of chlorinated hydrocarbons."/><PatentFamily id="2102047" number="US-06218395" title="Centrally-acting beta-blockers and serotonin-enhancers for the treatment of anxiety disorders and adjustment disorders with anxiety."/><PatentFamily id="2177916" number="US-06312717" title="Method for treatment of anxiety and depression."/><PatentFamily id="2199421" number="WO-00101989" title="Novel pharmaceutical combination with analgesic action containing paracetamol and buspirone"/><PatentFamily id="2241291" number="US-03717634" title="N-(Heteroarcyclic)Piperazinylalkyl-Azaspiroalkanediones"/><PatentFamily id="2270715" number="WO-09815277" title="CNS-penetrant NK-1 receptor antagonists as antidepressant and/or an anti-anxiety agent."/><PatentFamily id="2289564" number="CN-01977845" title="Hydraulic acid buspirone sustained-release pellets"/><PatentFamily id="2306068" number="US-04438119" title="Method For Alleviation Of Extrapyramidal Motor Disorders"/><PatentFamily id="2325814" number="WO-2005049041" title="Combinations comprising AMPA receptor antagonists for the treatment of anxiety disorders"/><PatentFamily id="2350196" number="WO-09932153" title="Monoglyceride and ethyl palmitate permeation enhancer compositions"/><PatentFamily id="23543" number="WO-00006163" title="Improved method for treatment of sleep-related respiratory disorders."/><PatentFamily id="2370729" number="WO-2012048710" title="Combinations of serotonin receptor agonists for treatment of movement disorders"/><PatentFamily id="2403952" number="WO-2012158030" title="Drug delivery system"/><PatentFamily id="2430452" number="WO-2012170599" title="Neurogenesis by muscarinic receptor modulation"/><PatentFamily id="2435028" number="MY-00120631" title="Novel pharmaceutical combination having analgesic activity"/><PatentFamily id="2447271" number="WO-2013004249" title="The use of serotonin receptor agonists for treatment of movement disorders"/><PatentFamily id="2504158" number="IN-00311837" title="Improved one pot process for synthesis of buspirone base"/><PatentFamily id="279030" number="US-20010009913" title="Anxiety method"/><PatentFamily id="3009736" number="WO-2015127558" title="Methods and uses for inducing or facilitating micturition in a patient in need thereof"/><PatentFamily id="3010118" number="WO-2015127556" title="Methods and uses for inducing or facilitating defecation in a patient in need thereof"/><PatentFamily id="3102331" number="WO-2015197079" title="Use of buspirone metabolites"/><PatentFamily id="3560121" number="WO-2017035512" title="Concerted use of noninvasive neuromodulation device with exoskeleton to enable voluntary movement and greater muscle activation when stepping in a chronically paralyzed subject"/><PatentFamily id="361704" number="WO-2005048954" title="Continuous process for producing hydroxyazapirones by oxidation"/><PatentFamily id="3796307" number="US-20170266184" title="Non addictive morphine plus buspirone combination for the treatment of pain"/><PatentFamily id="3863546" number="WO-2017204632" title="Process for the preparation of drug delivery systems having a testosterone compound present in an outer layer or part, as well as such drug delivery systems"/><PatentFamily id="402712" number="US-20030207890" title="Compounds with 5-HT1A activity useful for treating disorders of the outer retina"/><PatentFamily id="4122593" number="WO-2018129461" title="Treatment of sexual dysfunction"/><PatentFamily id="4244289" number="IN-201721013027" title="Pharmaceutical composition, comprises stable microemulsion, which comprises buspirone or its pharmaceutically acceptable form, oil phase, surfactants, cosurfactants, and excipients"/><PatentFamily id="4250155" number="WO-2018200959" title="Methods and composition related to combination therapy for addiction"/><PatentFamily id="4296909" number="CN-108872352" title="Method of ruthenium system electro-chemical light emitting method for measuring hydrochloric acid buspirone"/><PatentFamily id="4537767" number="WO-2019108093" title="Acetylleucine combinations for treating dizziness"/><PatentFamily id="460556" number="EP-00477624" title="Method for preventing or treating depression employing a combination of an ace inhibitor and a drug that acts at serotonin receptors."/><PatentFamily id="465063" number="EP-00680961" title="Improved, large-scale process for azapirone synthesis."/><PatentFamily id="468308" number="WO-00006160" title="Treating depression with a combination of fluoxetine (prozac), pindolol (visken) and buspirone (buspar)."/><PatentFamily id="581041" number="WO-2004071491" title="Aerosol formulations and aerosol delivery of buspirone, buprenorphine, triazolam, cyclobenzaprine and zolpidem"/><PatentFamily id="612229" number="US-05521313" title="Process for preparing certain azapirones"/><PatentFamily id="645305" number="US-04351939" title="Spiro-Quaternary Ammonium Halides And N-(2-Pyrimidinyl)Piperazinylalkylazaspiroalkanedione Process"/><PatentFamily id="687378" number="WO-09601106" title="Use of pharmaceutical agents for alleviation or treatment of the immune dysfunction related to infection with human  immunodeficiency viruses (HIV) or related viruses."/><PatentFamily id="755716" number="WO-09209252" title="Method and device for treating tobacco addiction"/><PatentFamily id="764632" number="GB-02089341" title="Buspirone Process"/><PatentFamily id="774621" number="WO-2007134077" title="5 HT receptor mediated neurogenesis"/><PatentFamily id="823317" number="EP-00497314" title="Use of azapirones in attention deficit hyperactivity disorder."/><PatentFamily id="829327" number="WO-08903676" title="Oral formulation of buspirone and salts thereof"/><PatentFamily id="830061" number="EP-00442424" title="Treatment of sleep apneas with azapirone derivatives."/><PatentFamily id="864801" number="WO-09913884" title="Compositions and methods useful for the treatment of neurological and mental disorders."/><PatentFamily id="875672" number="WO-2004014309" title="Improved process for hydroxyazapirones"/><PatentFamily id="877087" number="WO-00170223" title="Compounds with 5-HT2 and 5-HT1A agonist activity for treating glaucoma"/><PatentFamily id="948951" number="CN-01526394" title="Hydrochloric acid fourth screw ring ketone dropping pill and its preparation method"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>11</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>26</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="4">Delivery device</Type><Count>4</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>22</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>22</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Acrux Ltd" id="1003133"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Unichem Laboratories Ltd" id="1008072"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sanofi SA" id="1009547"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="BrainCells Inc" id="1015253"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Emotional Brain BV" id="1017828"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University Of Karachi" id="1038821"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Helioeast Science and Technology Pharmaceutical Co Ltd" id="1053815"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sihuan Pharmaceutical Holdings Group Ltd" id="1056556"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="TWi Pharmaceuticals Inc" id="1060616"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nordic Life Science Pipeline Inc" id="1066780"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nanjing ZeLang Medical Technology Co Ltd" id="1069838"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Valenta Intellekt" id="1072461"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Allergan plc" id="1088700"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Perrigo Co plc" id="1091305"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="EB IP Hybritabs BV" id="1157344"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Guangxi University of Science and Technology" id="1160496"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Olive Therapeutics LLC" id="1167877"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="AstraZeneca plc" id="14190"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bayer AG" id="14455"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bristol-Myers Squibb Co" id="15065"/><CountAsOwner>24</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>24</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bukwang Pharmaceutical Co Ltd" id="15280"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Celgene Corp" id="15331"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Earlow Ltd" id="15849"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hisamitsu Pharmaceutical Co Inc" id="16802"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Johnson &amp; Johnson" id="17332"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merck &amp; Co Inc" id="18077"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mylan NV" id="18439"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Alcon Inc" id="18478"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nitto Denko Corp" id="18574"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Orion Corp" id="18693"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Servier" id="19863"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of California" id="20547"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Emory University" id="20573"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hebrew University of Jerusalem" id="20586"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universite Laval" id="20602"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="New York University" id="20646"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of South Florida" id="20677"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Stanford University" id="20679"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>11</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>11</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Albany Molecular Research Inc" id="21199"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jinro Ltd" id="21291"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Theratechnologies Inc" id="22170"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Lonza Group AG" id="22690"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Medinnova AS" id="23072"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pharma Pass Inc" id="23239"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Boston Children's Hospital" id="24334"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Harvard Medical School" id="24839"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Arachnova Ltd" id="25572"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Heart Care Partners" id="26309"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Psychiatric Genomics Inc" id="27895"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="American Pharmaceuticals International" id="28937"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Reckitt Benckiser plc" id="29074"/><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chrysalis Technologies Inc" id="29713"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>